RecruitingPhase 3NCT06963216
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
A Phase III Open-Label Multi-Center Study of the Pharmacokinetics, Safety, and Efficacy of Coagadex in the Treatment of Adults With Acquired Factor X Deficiency Associated With Light Chain Amyloidosis
Sponsor
Kedrion S.p.A.
Enrollment
15 participants
Start Date
Feb 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of Coagadex in treating active bleeds and to manage peri-operative bleeding in participants with acquired factor X deficiency associated with AL amyloidosis.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria3
- Male or female participants ages 18-70 years old.
- Diagnosis of aFXD associated with AL amyloidosis with FX:C ≤ 50 IU/dL.
- Woman of Childbearing Potential (defined in Appendix 2) and men of reproductive potential who agree to use an effective contraception measure during the study.
Exclusion Criteria8
- Female participants that are pregnant or lactating.
- Presence of FX inhibitors.
- Uncontrolled arterial hypertension.
- On anticoagulant therapy (not antiplatelets), unstable heart disease, clinically significant thrombotic event in the past 180 days or any other condition that the Investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
- Any factor X containing product taken within 2 weeks of first Coagadex® administration.
- Participation in another interventional clinical study with an investigational drug, biologic, or device within 30 days prior to screening.
- Hemodynamically unstable due to any cause or even after blood transfusion, fluid resuscitation and pharmacologic or volume replacement pressor therapy.
- Prior history of bleeding disorder other than aFXD.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALCoagadex(R)
Coagulation Factor X (Human)
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06963216